146 related articles for article (PubMed ID: 37038617)
1. Baseline neutrophil-to-lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling.
Verma R; Moroney M; Hibino M; Mazer CD; Connelly KA; Yan AT; Quan A; Teoh H; Verma S; Puar P
ESC Heart Fail; 2023 Jun; 10(3):2127-2133. PubMed ID: 37038617
[TBL] [Abstract][Full Text] [Related]
2. IGFBP7 and left ventricular mass regression: a sub-analysis of the EMPA-HEART CardioLink-6 randomized clinical trial.
Puar P; Mistry N; Connelly KA; Yan AT; Quan A; Teoh H; Pan Y; Verma R; Hess DA; Verma S; Mazer CD
ESC Heart Fail; 2023 Jun; 10(3):2113-2119. PubMed ID: 37038626
[TBL] [Abstract][Full Text] [Related]
3. Impact of diabetes duration on left ventricular mass regression with empagliflozin.
Moroney M; Verma R; Hibino M; Mazer CD; Connelly KA; Yan AT; Quan A; Teoh H; Verma S; Puar P
ESC Heart Fail; 2023 Jun; 10(3):2134-2140. PubMed ID: 37038614
[TBL] [Abstract][Full Text] [Related]
4. Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin.
Puar P; Hibino M; Mazer CD; Yan AT; Pandey AK; Quan A; Teoh H; Hess DA; Verma R; Connelly KA; Verma S
Cardiovasc Diabetol; 2023 Jun; 22(1):152. PubMed ID: 37380983
[TBL] [Abstract][Full Text] [Related]
5. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
Connelly KA; Mazer CD; Puar P; Teoh H; Wang CH; Mason T; Akhavein F; Chang CW; Liu MH; Yang NI; Chen WS; Juan YH; Opingari E; Salyani Y; Barbour W; Pasricha A; Ahmed S; Kosmopoulos A; Verma R; Moroney M; Bakbak E; Krishnaraj A; Bhatt DL; Butler J; Kosiborod MN; Lam CSP; Hess DA; Rizzi Coelho-Filho O; Lafreniere-Roula M; Thorpe KE; Quan A; Leiter LA; Yan AT; Verma S
Circulation; 2023 Jan; 147(4):284-295. PubMed ID: 36335517
[TBL] [Abstract][Full Text] [Related]
7. Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial.
Barbour W; Wolff E; Puar P; Hibino M; Bakbak E; Krishnaraj A; Verma R; Verma M; Quan A; Yan AT; Connelly KA; Teoh H; Mazer CD; Verma S
BMC Cardiovasc Disord; 2023 Nov; 23(1):557. PubMed ID: 37964221
[TBL] [Abstract][Full Text] [Related]
8. Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes.
Sarak B; Verma S; David Mazer C; Teoh H; Quan A; Gilbert RE; Goodman SG; Bami K; Coelho-Filho OR; Ahooja V; Deva DP; Garg V; Gandhi S; Connelly KA; Yan AT
Cardiovasc Diabetol; 2021 Oct; 20(1):200. PubMed ID: 34607574
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease.
Mason T; Coelho-Filho OR; Verma S; Chowdhury B; Zuo F; Quan A; Thorpe KE; Bonneau C; Teoh H; Gilbert RE; Leiter LA; Jüni P; Zinman B; Jerosch-Herold M; Mazer CD; Yan AT; Connelly KA
JACC Cardiovasc Imaging; 2021 Jun; 14(6):1164-1173. PubMed ID: 33454272
[TBL] [Abstract][Full Text] [Related]
10. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials.
Dhingra NK; Mistry N; Puar P; Verma R; Anker S; Mazer CD; Verma S
ESC Heart Fail; 2021 Dec; 8(6):4693-4700. PubMed ID: 34623032
[TBL] [Abstract][Full Text] [Related]
13. The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: A meta-analysis of randomized controlled trials.
Fan G; Guo DL
Eur J Intern Med; 2023 Aug; 114():49-57. PubMed ID: 37062643
[TBL] [Abstract][Full Text] [Related]
14. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
[TBL] [Abstract][Full Text] [Related]
15. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
[TBL] [Abstract][Full Text] [Related]
16. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
17. Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study.
Cohen ND; Gutman SJ; Briganti EM; Taylor AJ
Intern Med J; 2019 Aug; 49(8):1006-1010. PubMed ID: 30784160
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes.
Lan NSR; Yeap BB; Fegan PG; Green G; Rankin JM; Dwivedi G
Int J Cardiovasc Imaging; 2021 Feb; 37(2):517-527. PubMed ID: 32959096
[TBL] [Abstract][Full Text] [Related]
19. Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
Oka S; Kai T; Hoshino K; Watanabe K; Nakamura J; Abe M; Watanabe A
BMC Cardiovasc Disord; 2021 Apr; 21(1):217. PubMed ID: 33926386
[TBL] [Abstract][Full Text] [Related]
20. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Santos-Gallego CG; Vargas-Delgado AP; Requena-Ibanez JA; Garcia-Ropero A; Mancini D; Pinney S; Macaluso F; Sartori S; Roque M; Sabatel-Perez F; Rodriguez-Cordero A; Zafar MU; Fergus I; Atallah-Lajam F; Contreras JP; Varley C; Moreno PR; Abascal VM; Lala A; Tamler R; Sanz J; Fuster V; Badimon JJ;
J Am Coll Cardiol; 2021 Jan; 77(3):243-255. PubMed ID: 33197559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
